C-reactive protein as a diagnostic and prognostic factor in inflammatory bowel diseases

Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue

Abstract

Aim: The study aimed to evaluate high-sensitivity CRP (hsCRP) as a diagnostic and predictive marker in patients with inflammatory bowel disease (IBD). Material/Methods: Medical history of 106 patients with IBD revealed hsCRP concentrations at diagnosis and during the follow-up period.Results: The study showed that the majority of investigated patients had elevated hsCRP concentrations at diagnosis, although the mean concentration was much higher in the group of patients with Crohn’s disease (CD) than the group with ulcerative colitis (UC) (P<0.001). The overall decrease in mean hsCRP concentration observed during the follow-up period was larger in the group of CD patients. The analysis showed a correlation between hsCRP concentrations at diagnosis and risk of surgery in the group of CD patients (r=0.408, P=0.002), but not in the group of UC patients. In a logistic regression analysis, surgery in CD patients was associated with age (OR: 0.89, 95% CI: 0.8–1.0, P=0.05) and hsCRP concentration (OR: 1.02, 95% CI: 1.0–1.04, P=0.03) at diagnosis.Discussion: HsCRP might be a useful diagnostic marker in differentiating active IBD from other diseases. Particularly important however seems to be the predictive value of hsCRP at diagnosis in prognosing the clinical outcome of the disease in CD patients.

Authors and Affiliations

Dorota Mańkowska-Wierzbicka, Jacek Karczewski, Barbara Poniedziałek, Małgorzata Grzymisławska, Rafał Staszewski, Aleksandra Królczyk, Agnieszka Dobrowolska, Marian Grzymisławski

Keywords

Related Articles

Phytochemicals that counteract the cardiotoxic side effects of cancer chemotherapy

Almost all clinically used antitumor drugs exhibit toxic side effects affecting heart function. Because of cardiotoxicity during anticancer chemotherapy, effective doses of cytostatics have to be limited, which may worse...

Potential therapeutic interventions via EP2/EP4 prostaglandin receptors

Prevention and treatment of pathological inflammatory processes requires application of various classes of immune suppressors, such as calcineurin inhibitors, steroids and non-steroid inhibitors of prostaglandin synthesi...

Eukaryotic TLS polymerases

TLS polymerases are able to replicate damaged DNA (called translesion DNA synthesis, TLS). Their presence prevents cell death as a result of violating the integrity of the genome. In vitro, they are mutator, but in vivo...

Effect of allograft inflammatory factor-1 gene polymorphisms on rheumatoid arthritis treatment with methotrexate

Objective: Methotrexate (MTX) in low doses is used in the therapy of rheumatoid arthritis (RA). The aim of many studies is to identify factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis...

Download PDF file
  • EP ID EP220876
  • DOI -
  • Views 151
  • Downloads 0

How To Cite

Dorota Mańkowska-Wierzbicka, Jacek Karczewski, Barbara Poniedziałek, Małgorzata Grzymisławska, Rafał Staszewski, Aleksandra Królczyk, Agnieszka Dobrowolska, Marian Grzymisławski (2016). C-reactive protein as a diagnostic and prognostic factor in inflammatory bowel diseases. Advances in Hygiene and Experimental Medicine, 70(), 1124-1130. https://europub.co.uk/articles/-A-220876